|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 333,99 USD | -1,15% |
|
+4,27% | +9,93% |
| 08/01 | BEONE MEDICINES AG : RBC Capital Markets herhaalt koopadvies | ZM |
| 06/01 | BeOne Medicines Ltd. maakt volledige resultaten bekend van de fase 3 Herizon-Gea-01-studie naar Ziihera | CI |
Voorlopige winst- en verliesrekening: BeOne Medicines AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 308,9 | 1.176 | 1.416 | 2.459 | 3.810 | 5.296 | 6.427 | 7.464 |
| Variatie | - | 280,83% | 20,37% | 73,65% | 54,96% | 38,99% | 21,35% | 16,15% |
| EBITDA 1 | -1.626 | -1.392 | -1.723 | -1.120 | -396,4 | 526,8 | 973,5 | 1.548 |
| Variatie | - | 14,37% | -23,78% | 35,01% | 64,61% | 232,88% | 84,81% | 58,97% |
| Bedrijfsresultaat (EBIT) 1 | -1.658 | -1.439 | -1.790 | -1.208 | -568,2 | 348,1 | 765,5 | 1.267 |
| Variatie | - | 13,21% | -24,39% | 32,52% | 52,95% | 161,26% | 119,93% | 65,53% |
| Betaalde rente 1 | 1,998 | -15,76 | 52,48 | 74,01 | 7,808 | -24,18 | -24,71 | -36,93 |
| Resultaat voor belastingen (EBT) 1 | -1.618 | -1.439 | -1.961 | -825,8 | -533 | 382 | 814,4 | 1.354 |
| Variatie | - | 11,1% | -36,32% | 57,89% | 35,46% | 171,67% | 113,19% | 66,22% |
| Nettowinst (verlies) 1 | -1.597 | -1.413 | -2.004 | -881,7 | -644,8 | 329,1 | 692,5 | 1.157 |
| Variatie | - | 11,49% | -41,78% | 56% | 26,87% | 151,04% | 110,42% | 67,08% |
| Datum van publicatie | 25-02-21 | 25-02-22 | 27-02-23 | 26-02-24 | 27-02-25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Balansprognose: BeOne Medicines AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | -4.132 | -3.746 | -3.332 | -2.297 | -1.609 | -2.336 | -2.962 | -3.976 |
| Variatie | - | 9,34% | 11,05% | 31,06% | 29,95% | -45,15% | -26,8% | -34,23% |
| Datum van publicatie | 25-02-21 | 25-02-22 | 27-02-23 | 26-02-24 | 27-02-25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte kasstroom: BeOne Medicines AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 117,5 | 262,9 | 325,4 | 561,9 | 492,7 | 305,8 | 305,4 | 319,8 |
| Variatie | - | 123,77% | 23,77% | 72,66% | -12,32% | -37,94% | -0,13% | 4,73% |
| Vrije kasstroom (FCF) 1 | -1.401 | -1.562 | -1.822 | -1.719 | -633,3 | 421,8 | 814 | 1.338 |
| Variatie | - | -11,47% | -16,67% | 5,64% | 63,17% | 166,6% | 92,99% | 64,37% |
| Datum van publicatie | 25-02-21 | 25-02-22 | 27-02-23 | 26-02-24 | 27-02-25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: BeOne Medicines AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | -526,39% | -118,36% | -121,71% | -45,55% | -10,4% | 9,95% | 15,15% | 20,73% |
| EBIT-marge (%) | -536,69% | -122,31% | -126,4% | -49,12% | -14,91% | 6,57% | 11,91% | 16,98% |
| EBT-marge (%) | -523,9% | -122,3% | -138,5% | -33,59% | -13,99% | 7,21% | 12,67% | 18,14% |
| Nettomarge (%) | -517,01% | -120,15% | -141,52% | -35,86% | -16,92% | 6,21% | 10,78% | 15,5% |
| FCF-marge (%) | -453,57% | -132,76% | -128,68% | -69,93% | -16,62% | 7,96% | 12,67% | 17,92% |
| Vrije kasstroom/nettoresultaat (%) | 87,73% | 110,49% | 90,93% | 195% | 98,22% | 128,15% | 117,53% | 115,63% |
Winstgevendheid | ||||||||
| ROA | -44,28% | -19,84% | -26,87% | -14,47% | -11% | 4,35% | 8,95% | 11,55% |
| ROE | -66,1% | -27,95% | -38,11% | -22,26% | -18,77% | 10,64% | 17,62% | 23,61% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - | - |
| Schuld/vrije kasstroom | - | - | - | - | - | - | - | - |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 38,04% | 22,35% | 22,98% | 22,85% | 12,93% | 5,77% | 4,75% | 4,28% |
| CAPEX / EBITDA (%) | -7,23% | -18,89% | -18,88% | -50,17% | -124,27% | 58,04% | 31,37% | 20,66% |
| CAPEX / FCF (%) | -8,39% | -16,84% | -17,86% | -32,68% | -77,79% | 72,5% | 37,52% | 23,9% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | -15,38 | -14 | -14,51 | -11,09 | -1,336 | 13,7 | 11 | 14,6 |
| Variatie | - | 8,97% | -3,68% | 23,59% | 87,95% | 1.125,68% | -19,71% | 32,73% |
| Dividend per aandeel 1 | - | - | - | - | - | - | - | - |
| Variatie | - | - | - | - | - | - | - | - |
| Nettoactief per aandeel 1 | 46,35 | 67,28 | 42,5 | 33,89 | 31,65 | 36,14 | 45,58 | 58,86 |
| Variatie | - | 45,15% | -36,83% | -20,27% | -6,6% | 14,19% | 26,13% | 29,14% |
| WPA 1 | -19,13 | -15,23 | -19,43 | -8,45 | -6,12 | 3,269 | 6,549 | 10,1 |
| Variatie | - | 20,39% | -27,58% | 56,51% | 27,57% | 153,41% | 100,37% | 54,27% |
| Aantal aandelen (in duizend) | 90.924 | 102.770 | 103.859 | 104.578 | 106.476 | 110.658 | 110.658 | 110.658 |
| Datum van publicatie | 25-02-21 | 25-02-22 | 27-02-23 | 26-02-24 | 27-02-25 | - | - | - |
1USD
Geschatte gegevens
| 2025 * | 2026 * | |
|---|---|---|
| k/w-verhouding | 103x | 51,6x |
| PBR-ratio | 9,35x | 7,41x |
| EV/omzet | 6,54x | 5,29x |
| Dividendrendement | - | - |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Trader
Trader
Beleggings
Beleggings
Globaal
Globaal
Kwaliteit van de publicaties
Kwaliteit van de publicaties
ESG MSCI
-
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
26
Laatste slotkoers
337,89USD
Gemiddelde koersdoel
402,18USD
Spread / Gemiddelde doel
+19,03%
Kwartaalomzet - Afwijkingspercentage
Kies jouw editie
Alle financiële informatie op nationaal niveau
